Does Dr. ANDREW GERMANOVICH have financial conflicts of interest?

Dr. ANDREW GERMANOVICH (D.O., M.S.) has received a total of $127,595 in pharmaceutical and medical device industry funding between 2021 and 2025. This includes $123,889 in personal promotional payouts (consulting, meals, travel) and $3,706 in clinical research grants. Financial ties do not automatically imply conflict of interest, but are disclosed under the Sunshine Act.

Which pharmaceutical companies pay Dr. ANDREW GERMANOVICH?

According to CMS Open Payments data, Dr. ANDREW GERMANOVICH received funding from MASIMO CORPORATION ($116,071), BIOHAVEN PHARMACEUTICALS ($1,458), and ABBVIE ($1,135).

Does Dr. ANDREW GERMANOVICH receive research grants or speaking fees?

Dr. ANDREW GERMANOVICH has received $123,889 in general promotional payments (such as consulting honoraria, meals, and speaking fees) and $3,706 in clinical research grants.

DR. ANDREW GERMANOVICH

D.O., M.S.Real-Time Hydrated

Specialty: Pain Medicine, Interventional Pain Medicine

Practice Location: ORANGE, CA 92868

NPI Number: 1043479835

LIFETIME INDUSTRY VALUE

$127,595

2021 – 2025 Cumulative

Conflict of Interest Analysis

Dr. GERMANOVICH is a verified Pain Medicine, Interventional Pain Medicine practitioner based in ORANGE, CA.

Between 2021 and 2025, Dr. GERMANOVICH had an overall industry promotional and research financial footprint of $127,595 as recorded in the federal CMS Open Payments database.

$123,889 was received in general payments, which include consultation fees, travel expenses, honoraria, and sponsored meals.
$3,706 was allocated to sponsored clinical trials and medical research activities.

Dr. GERMANOVICH's primary funding source is MASIMO CORPORATION, which accounts for $116,071 (representing 91% of overall industry footprint).

Data coverage: 2021 – 2025 · Source: CMS Open Payments · CMS publishes each year's data around June 30 of the following year.

Payout Trend Over Time

General Payments

Research Funding

Top Funding Entities

Pharmaceutical & Device Manufacturers making direct payments

MASIMO CORPORATION

Rank 1

$116,071

91%

BIOHAVEN PHARMACEUTICALS

Rank 2

$1,458

1.1%

ABBVIE

Rank 3

$1,135

0.9%

Itemized Transaction Archives

Direct live query to Socrata CMS Open Payments API (Bypasses local DB)

Year:

2025

Filter < $250

Click "Load Live Logs" to query the federal Open Payments registry directly.

Frequently Asked Questions

Answers compiled using federal transparency disclosure records under the Sunshine Act.